SitesBLAST
Comparing WP_090274945.1 NCBI__GCF_900105005.1:WP_090274945.1 to proteins with known functional sites using BLASTp with E ≤ 0.001.
Or try Sites on a Tree, PaperBLAST, Conserved Domains, or compare to all protein structures
Found 20 (the maximum) hits to proteins with known functional sites (download)
P07117 Sodium/proline symporter; Proline carrier; Proline permease; Propionate transporter from Escherichia coli (strain K12) (see 4 papers)
48% identity, 99% coverage: 8:500/500 of query aligns to 8:491/502 of P07117
- R257 (= R268) mutation to C: Sodium-independent binding affinity for proline.
- C281 (≠ V292) mutation to S: Does not affect proline uptake activity. Confers resistance to N-ethylmaleimide. Na(+)-dependent proline binding activity is similar to wild-type carrier.
- C344 (≠ S351) mutation to S: Small decrease in proline uptake activity. Confers resistance to N-ethylmaleimide. Exhibits low Na(+)-dependent proline binding.
- C349 (= C356) mutation to S: Does not affect proline uptake activity. Sensitive to N-ethylmaleimide. Na(+)-dependent proline binding activity is similar to wild-type carrier.
- R376 (= R382) mutation R->E,Q: No change in activity.; mutation to K: Loss of activity.
Q92911 Sodium/iodide cotransporter; Na(+)/I(-) cotransporter; Natrium iodide transporter; Sodium-iodide symporter; Na(+)/I(-) symporter; Solute carrier family 5 member 5 from Homo sapiens (Human) (see 3 papers)
24% identity, 84% coverage: 33:450/500 of query aligns to 45:436/643 of Q92911
- A102 (≠ W90) natural variant: A -> P
- H226 (= H220) mutation H->A,D,E,K: Significant loss of iodide transport activity but no effect on its localization to the cell membrane.
- D237 (≠ G232) mutation to A: Loss of localization to the cell membrane, significant loss of iodide transport activity but no effect on homodimerization.
- Y242 (≠ R237) Required for homodimerization; mutation to A: Loss of localization to the cell membrane, significant loss of iodide transport activity but no effect on homodimerization. Reduced homodimerization; when associated with A-471. Loss of iodide transport activity; when associated with F-535.
- T243 (= T238) Required for homodimerization; mutation to A: Loss of localization to the cell membrane, significant loss of iodide transport activity but no effect on homodimerization. Reduced homodimerization; when associated with A-471.
Sites not aligning to the query:
- 471 Required for homodimerization; Q→A: No effect on localization to the cell membrane, iodide transport activity and homodimerization. Significant loss of homodimerization; when associated with A-242 or A243.
- 525 A→F: Loss of localization to the cell membrane, significant loss of iodide transport activity but no effect on homodimerization. Loss of iodide transport activity; when associated with A-242.
- 536 T → Q: requires 2 nucleotide substitutions
- 556 S → Q: requires 2 nucleotide substitutions
Q8N695 Sodium-coupled monocarboxylate transporter 1; Apical iodide transporter; Electrogenic sodium monocarboxylate cotransporter; Sodium iodide-related cotransporter; Solute carrier family 5 member 8 from Homo sapiens (Human) (see 3 papers)
23% identity, 89% coverage: 23:465/500 of query aligns to 31:467/610 of Q8N695
- V193 (≠ G191) to I: in dbSNP:rs1709189
- F251 (≠ L246) to V: in dbSNP:rs11834933
Sites not aligning to the query:
- 608 T→A: Loss of interaction with PDZK1.
- 608:610 PDZ-binding
- 610 L→A: Loss of interaction with PDZK1.
3dh4A Crystal structure of sodium/sugar symporter with bound galactose from vibrio parahaemolyticus (see paper)
25% identity, 67% coverage: 109:441/500 of query aligns to 84:426/512 of 3dh4A
Sites not aligning to the query:
8hezA Structure of human sglt2-map17 complex with dapagliflozin (see paper)
26% identity, 76% coverage: 3:383/500 of query aligns to 1:408/582 of 8hezA
- binding (2S,3R,4R,5S,6R)-2-[4-chloranyl-3-[(4-ethoxyphenyl)methyl]phenyl]-6-(hydroxymethyl)oxane-3,4,5-triol: N55 (≠ D55), G59 (≠ W59), H60 (≠ L60), G63 (= G63), L64 (= L64), T67 (≠ A67), F78 (vs. gap), E79 (vs. gap), V266 (≠ I250), S267 (= S251), W271 (= W255), K301 (vs. gap)
- binding sodium ion: A53 (= A53), I56 (≠ M56), G57 (≠ S57), A369 (= A344), S372 (= S347), S373 (≠ T348)
Sites not aligning to the query:
- binding (2S,3R,4R,5S,6R)-2-[4-chloranyl-3-[(4-ethoxyphenyl)methyl]phenyl]-6-(hydroxymethyl)oxane-3,4,5-triol: 433, 437
- binding : 568, 571, 572, 575, 576, 579, 580
8hg7A Structure of human sglt2-map17 complex with sotagliflozin (see paper)
26% identity, 76% coverage: 3:383/500 of query aligns to 1:408/590 of 8hg7A
- binding (2S,3R,4R,5S,6R)-2-[4-chloranyl-3-[(4-ethoxyphenyl)methyl]phenyl]-6-methylsulfanyl-oxane-3,4,5-triol: N55 (≠ D55), G59 (≠ W59), H60 (≠ L60), G63 (= G63), L64 (= L64), E79 (vs. gap), V266 (≠ I250), S267 (= S251), Y270 (≠ S254), W271 (= W255), K301 (vs. gap)
- binding sodium ion: A53 (= A53), S54 (= S54), I56 (≠ M56), G57 (≠ S57), A369 (= A344), S372 (= S347), S373 (≠ T348)
Sites not aligning to the query:
- binding (2S,3R,4R,5S,6R)-2-[4-chloranyl-3-[(4-ethoxyphenyl)methyl]phenyl]-6-methylsulfanyl-oxane-3,4,5-triol: 433, 437
- binding : 579, 583, 584, 587, 588
8hdhA Structure of human sglt2-map17 complex with canagliflozin (see paper)
26% identity, 76% coverage: 3:383/500 of query aligns to 1:408/586 of 8hdhA
- binding (2~{S},3~{R},4~{R},5~{S},6~{R})-2-[3-[[5-(4-fluorophenyl)thiophen-2-yl]methyl]-4-methyl-phenyl]-6-(hydroxymethyl)oxane-3,4,5-triol: N55 (≠ D55), G59 (≠ W59), H60 (≠ L60), G63 (= G63), L64 (= L64), F78 (vs. gap), E79 (vs. gap), S267 (= S251), W271 (= W255)
- binding sodium ion: A53 (= A53), S54 (= S54), I56 (≠ M56), G57 (≠ S57), A369 (= A344), S372 (= S347), S373 (≠ T348)
Sites not aligning to the query:
- binding (2~{S},3~{R},4~{R},5~{S},6~{R})-2-[3-[[5-(4-fluorophenyl)thiophen-2-yl]methyl]-4-methyl-phenyl]-6-(hydroxymethyl)oxane-3,4,5-triol: 433, 434, 437, 506
- binding : 575, 579, 580, 583, 584
8hb0A Structure of human sglt2-map17 complex with ta1887 (see paper)
26% identity, 76% coverage: 3:383/500 of query aligns to 1:408/586 of 8hb0A
- binding (2R,3R,4S,5S,6R)-2-[3-[(4-cyclopropylphenyl)methyl]-4-fluoranyl-indol-1-yl]-6-(hydroxymethyl)oxane-3,4,5-triol: N55 (≠ D55), H60 (≠ L60), G63 (= G63), L64 (= L64), T67 (≠ A67), V75 (≠ E75), F78 (vs. gap), E79 (vs. gap), V137 (≠ S143), V266 (≠ I250), S267 (= S251), W271 (= W255)
- binding sodium ion: A53 (= A53), I56 (≠ M56), G57 (≠ S57), A369 (= A344), S372 (= S347), S373 (≠ T348)
Sites not aligning to the query:
- binding (2R,3R,4S,5S,6R)-2-[3-[(4-cyclopropylphenyl)methyl]-4-fluoranyl-indol-1-yl]-6-(hydroxymethyl)oxane-3,4,5-triol: 433, 437
- binding : 575, 576, 579, 580, 583, 584
7vsiA Structure of human sglt2-map17 complex bound with empagliflozin (see paper)
26% identity, 76% coverage: 3:383/500 of query aligns to 1:408/586 of 7vsiA
- binding (2S,3R,4R,5S,6R)-2-[4-chloranyl-3-[[4-[(3S)-oxolan-3-yl]oxyphenyl]methyl]phenyl]-6-(hydroxymethyl)oxane-3,4,5-triol: N55 (≠ D55), H60 (≠ L60), G63 (= G63), L64 (= L64), V75 (≠ E75), F78 (vs. gap), E79 (vs. gap), V266 (≠ I250), S267 (= S251), Y270 (≠ S254)
Sites not aligning to the query:
P31639 Sodium/glucose cotransporter 2; Na(+)/glucose cotransporter 2; Low affinity sodium-glucose cotransporter; Solute carrier family 5 member 2 from Homo sapiens (Human) (see 2 papers)
26% identity, 77% coverage: 1:383/500 of query aligns to 19:428/672 of P31639
- A73 (= A53) binding Na(+)
- S74 (= S54) mutation to A: Impairs phlorizin binding and its inhibition on glucose uptake.
- I76 (≠ M56) binding Na(+)
- V95 (≠ E75) mutation to I: Strong reduction in D-glucose transporter activity. Impairs inhibition by empagliflozin on glucose uptake.
- F98 (vs. gap) mutation to A: Slightly decreases D-glucose transporter activity. Abolishes empagliflozin binding and its inhibition on glucose uptake. Impairs phlorizin binding and its inhibition on glucose uptake.
- V157 (≠ S143) mutation to A: Decreases D-glucose transporter activity. Impairs inhibition by empagliflozin on glucose uptake.
- D201 (= D187) mutation to A: Impairs phlorizin binding and its inhibition on glucose uptake.
- L283 (= L247) mutation to M: Strong reduction in D-glucose transporter activity. Impairs inhibition by empagliflozin on glucose uptake.
- A389 (= A344) binding Na(+)
- S392 (= S347) binding Na(+)
- S393 (≠ T348) binding Na(+)
Sites not aligning to the query:
- 453 F→A: Slightly decreases D-glucose transporter activity. Impairs empagliflozin binding and its inhibition on glucose uptake. Impairs phlorizin binding and its inhibition on glucose uptake.
P11170 Sodium/glucose cotransporter 1; Na(+)/glucose cotransporter 1; High affinity sodium-glucose cotransporter; Solute carrier family 5 member 1 from Oryctolagus cuniculus (Rabbit) (see 2 papers)
22% identity, 87% coverage: 11:443/500 of query aligns to 32:492/662 of P11170